Tamura Hideto, Ishibashi Mariko, Sunakawa-Kii Mika, Inokuchi Koiti
Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center, Saitama 343-8555, Japan.
Department of Hematology, Nippon Medical School, Tokyo 113-8603, Japan.
Cancers (Basel). 2020 Apr 10;12(4):924. doi: 10.3390/cancers12040924.
PD-L1 expressed on tumor cells contributes to disease progression with evasion from tumor immunity. Plasma cells from multiple myeloma (MM) patients expressed higher levels of PD-L1 compared with healthy volunteers and monoclonal gammopathy of undetermined significance (MGUS) patients, and its expression is significantly upregulated in relapsed/refractory patients. Furthermore, high PD-L1 expression is induced by the myeloma microenvironment and PD-L1 patients with MGUS and asymptomatic MM tend to show disease progression. PD-L1 expression on myeloma cells was associated with more proliferative potential and resistance to antimyeloma agents because of activation of the Akt pathway through PD-1-bound PD-L1 in MM cells. Those data suggest that PD-L1 plays a crucial role in the disease progression of MM.
肿瘤细胞上表达的程序性死亡受体配体1（PD-L1）通过逃避免疫监视促进疾病进展。与健康志愿者和意义未明的单克隆丙种球蛋白病（MGUS）患者相比，多发性骨髓瘤（MM）患者的浆细胞表达更高水平的PD-L1，且其表达在复发/难治性患者中显著上调。此外，骨髓瘤微环境可诱导PD-L1高表达，MGUS和无症状MM患者中PD-L1表达增高往往提示疾病进展。骨髓瘤细胞上PD-L1的表达与更高的增殖潜能及对抗骨髓瘤药物的耐药性相关，这是因为MM细胞中通过与程序性死亡受体1（PD-1）结合的PD-L1激活了Akt信号通路。这些数据表明，PD-L1在MM疾病进展中起关键作用。
